EXEL vs OMCL: fair value comparison
Exelixis, Inc. and Omnicell, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EXEL currently sits closer to the top of our discount ranking. EXEL carries the stronger quality grade.
| EXEL | OMCL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $55.06 | $37.65 |
| 12-month range | $37.18–$55.06 | $29.96–$48.70 |
| Sector rank | #48 of 113 Healthcare | #52 of 113 Healthcare |
| Quality grade | A | D |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Downtrend |
| DCF cross-check | Fairly Valued | — |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: EXEL fair value analysis · OMCL fair value analysis